Analyst consensus rating
Monopar Therapeutics Analyst Rating: none
Direct answer
Monopar Therapeutics's consensus rating is none.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $129.92.
Forecast evidence checked October 19, 2026.
Get free Monopar Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $69.27
- Average price target
- $129.92
- High price target
- $145.00
- Low price target
- $119.00
- Low target gap
- +71.8%
- Target upside
- +87.6%
- High target gap
- +109.3%
- Target range width
- 37.5%
- Consensus rating
- none
- Analysts
- 12
- Evidence date
- October 19, 2026
- Valid through
- October 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Monopar Therapeutics?
Monopar Therapeutics has a verified none consensus. The same dataset has an average price target of $129.92.
How far are Monopar Therapeutics's low and high targets from the recorded price?
The low target implies +71.8%, while the high target implies +109.3%.
How many analysts are included in Monopar Therapeutics's consensus?
The verified consensus includes 12 analysts.
How is Monopar Therapeutics's target upside or downside calculated?
The average target of $129.92 is divided by the recorded price of $69.27, then one is subtracted to produce +87.6%. This does not guarantee a future return.
When was Monopar Therapeutics's analyst forecast verified?
The data was verified on 2026-10-19. The dataset is valid through 2026-10-26.